Our Mission
Transform deadly cancer into a chronic and eventually curable disease
Our mission Our mission
We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discoveries with seven drug candidates in development. 


We have assembled best-in-class management team, built our unique immuno-oncology platforms and partnered with leading multi-national pharmaceutical companies to promote innovation. We are committed to becoming an innovative biotechnology company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform deadly cancer into a chronic and eventually curable disease.


Our Vision
To be a leading global presence in the immuno-oncology market
Our vision Our vision

Become a global leader in the emerging next wave of immuno-oncology therapies that employ a combination therapy strategy.

Introduction to our mission
2022


The first patient dosed in phase I clinical trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for advanced tumors


Publication of preclinical research of AN3025 (anti-hTNFR2)in Frontiers in Immunology

Introduction to our mission
2021

The first patient was dosed in China for the global Phase III clinical trial of AN2025 in combination with paclitaxel for the treatment of patients with recurrent or metastatic HNSCC


Five international renowned experts joining our Scientific Advisory Board as the initial members


Raised US$97.4 million in series D investments


Obtained IND clearance for AN4005 for the treatment of advanced tumors from the FDA


Introduction to our mission
2020

Raised approximately US$63.7 million in series C investments

 

Entered global clinical collaborations with partner A to evaluate a triple combination of AN2025 (buparlisib), AN0025 and Tecentriq®

 

Received the approval from the NMPA to initiate a Phase III multi-center clinical trial of AN2025 in combination with paclitaxel for the treatment of patients with recurrent or metastatic HNSCC

 

The first patient was dosed in the United States for Phase Ib clinical trial of AN0025 in combination with Keytruda


Introduction to our mission
2019

AN1004 received an approval from the NMPA for our initiation of a phase III clinicaltrial for AN1004 in combination with paclitaxel in patients with HR+/HER2- mBC


Entered global clinical collaboration with partner B to evaluate the combination of AN0025 and Keytruda for the treatment of solid tumors


Presented encouraging phase Ib study data of AN0025 at ESMO Congress 2019


Introduction to our mission
2018

Obtained the multi-national rights of E7046 (AN0025) through our in-licensing agreement with Eisai and took over the phase Ib clinical trial study of AN0025 from Eisai

 

Adlai Nortye (US) was incorporated

 

Raised approximately US$52.8 million in series B investments


Introduction to our mission
2017

Obtained the global rights of buparlisib (AN2025) through our in-licensing agreement with Novartis


Obtained regional rights of pelareorep (AN1004) through our in-licensing agreement with Oncolytics Biotech


Introduction to our mission
2016

Hangzhou subsidiary was 

converted into a joint stock limited company


Rebranded as Adlai Nortye Biopharma and transformed into clinical stage biotechnology company focusing immuno-oncology products


Introduction to our mission
2015

Raised approximately US$5.4 million in series A investments


Introduction to our mission
2004

Adlai Nortye Biopharma (formerly known as Hangzhou Nuotai Pharmaceutical Co., Ltd.) was established